Published in Nephrol News Issues on September 01, 2014
Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. N Engl J Med (2013) 3.15
Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol (2007) 1.61
Hyponatremia in community-acquired pneumonia. Am J Nephrol (2007) 1.59
Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol (2008) 1.54
Prevalence of depression in chronic kidney disease: systematic review and meta-analysis of observational studies. Kidney Int (2013) 1.52
History-adjusted marginal structural analysis of the association between hemoglobin variability and mortality among chronic hemodialysis patients. Clin J Am Soc Nephrol (2008) 1.49
Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int (2003) 1.30
A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int (2002) 1.30
Evidence and implications of haemoglobin cycling in anaemia management. Nephrol Dial Transplant (2007) 1.20
Occult infection of old nonfunctioning arteriovenous grafts: a novel cause of erythropoietin resistance and chronic inflammation in hemodialysis patients. Kidney Int Suppl (2002) 1.15
Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. Kidney Int (2002) 1.15
Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients. Kidney Int (2003) 1.11
Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study. Clin J Am Soc Nephrol (2008) 1.06
Erythropoietic stimulating agents and quality of a patient's life: individualizing anemia treatment. Clin J Am Soc Nephrol (2012) 1.03
More on renal salt wasting without cerebral disease: response to saline infusion. Clin J Am Soc Nephrol (2009) 1.01
Recombinant human erythropoietin: has treatment reached its full potential? Semin Dial (2006) 0.98
Serum ferritin in chronic kidney disease: reconsidering the upper limit for iron treatment. Semin Dial (2004) 0.96
Increased bone fractures among elderly United States hemodialysis patients. Nephrol Dial Transplant (2013) 0.93
Managing anemia in dialysis patients: hemoglobin cycling and overshoot. Kidney Int (2008) 0.92
The beliefs and expectations of patients and caregivers about home haemodialysis: an interview study. BMJ Open (2013) 0.86
Upper limit of serum ferritin: misinterpretation of the 2006 KDOQI anemia guidelines. Semin Dial (2008) 0.84
Implications of neocytolysis for optimal management of anaemia in chronic kidney disease. Nephron Clin Pract (2007) 0.83
Treating desmopressin-induced hyponatremia: a case using hypertonic saline. Clin Nephrol (2013) 0.83
How can erythropoietin requirements be reduced in dialysis patients? Semin Dial (2006) 0.82
Cardiovascular risk evaluation before kidney transplantation. J Am Soc Nephrol (2005) 0.82
CHOIR, CREATE, and anemia treatment in patients with CKD. Semin Dial (2007) 0.81
Meeting the 2012 QIP (Quality Incentive Program) clinical measures: strategies for dialysis centers. Am J Kidney Dis (2012) 0.80
Novel iron-based phosphate binders in patients with chronic kidney disease. Curr Opin Nephrol Hypertens (2015) 0.79
Clinician beliefs and attitudes about home haemodialysis: a multinational interview study. BMJ Open (2012) 0.79
The new label for erythropoiesis stimulating agents: the FDA'S sentence. Semin Dial (2012) 0.79
Drug insight: Safety of intravenous iron supplementation with sodium ferric gluconate complex. Nat Clin Pract Nephrol (2006) 0.79
Peginesatide for anemia in chronic kidney disease. N Engl J Med (2013) 0.79
Risk for acute renal failure in patients hospitalized for decompensated congestive heart failure. Am J Nephrol (2007) 0.78
The optimal hemoglobin in dialysis patients- a critical review. Semin Dial (2008) 0.78
Pheochromocytoma multisystem crisis in a patient with multiple endocrine neoplasia type IIB and pyelonephritis. Am J Kidney Dis (2002) 0.78
Hemoglobin variability: random fluctuation, epiphenomenon, or phenomenon? Semin Dial (2006) 0.78
Safety issues with iron sucrose. Am J Kidney Dis (2003) 0.78
Contribution of prostaglandin D2 synthase to progression of renal failure and dialysis dementia. Semin Nephrol (2002) 0.78
Longitudinal predictors of uremic pruritus. J Ren Nutr (2013) 0.78
Update on membranoproliferative GN. Clin J Am Soc Nephrol (2014) 0.78
How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: The use of iron supplementation to reduce ESA dosing in hemodialysis. Semin Dial (2013) 0.77
The effect of ergocalciferol on uremic pruritus severity: a randomized controlled trial. J Ren Nutr (2013) 0.77
Tenecteplase for the improvement of blood flow rate in dysfunctional hemodialysis catheters. Clin Nephrol (2012) 0.77
The effect of a change in epoetin alfa reimbursement policy on anemia outcomes in hemodialysis patients. Hemodial Int (2005) 0.77
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients. Am J Nephrol (2017) 0.77
A physician's perseverance uncovers problems in a key nephrology study. Kidney Int (2012) 0.76
Hepatic iron in hemodialysis patients. Kidney Int (2004) 0.76
Increasing hip fractures in patients receiving hemodialysis and peritoneal dialysis. Am J Nephrol (2014) 0.75
Dialysis: ESA responsiveness and outcomes in patients on hemodialysis. Nat Rev Nephrol (2011) 0.75
EPO adjuvant treatments: a need for more evidence. Am J Kidney Dis (2006) 0.75
Glomerular diseases: entering a new era. Clin J Am Soc Nephrol (2014) 0.75
Quality of reporting of randomization methodology in nephrology trials. Kidney Int (2012) 0.75
Meeting new challenges in the management of anemia of chronic kidney disease through collaborative care with pharmacists. Ann Pharmacother (2009) 0.75
How should chronic medical therapies be altered with the onset of end-stage renal disease and initiation of dialysis? Semin Dial (2006) 0.75
Management of isolated aspergilloma causing obstruction of the kidney transplant. Am J Kidney Dis (2010) 0.75
Nephrology Crossword: Onco-nephrology--chemotherapy agents and nephrotoxicity. Kidney Int (2013) 0.75
Forty-eight hour kidney transplant admissions. Clin Transplant (2013) 0.75
Quality outcomes and obstacles to their achievement in end-stage renal disease. Semin Dial (2002) 0.75
Ranolazine, tacrolimus, and diltiazem might be a hazardous combination in a transplant patient. Ren Fail (2012) 0.75
The effect of hemodialysis ultrafiltration on changes in whole blood viscosity. Hemodial Int (2012) 0.75